Lilly plans additional study of solanezumab for Alzheimer’s
Eli Lilly & Company has announced it plans additional study of solanezumab, an experimental Alzheimer’s drug that previously failed to improve the condition of people with the disease. The company released results of two clinical trials in August that showed the drug did not significantly improve cognition or daily mental function of people with mild and moderate Alzheimer’s. However, when the results for people with mild Alzheimer’s were separated out, they showed the drug did slow cognitive decline.
Read the article >>
Learn more about treatments >>
http://www.optimumseniorcare.com/services/alzheimerscare.php